Core Viewpoint - Suzhou Fengbei Biotechnology Co., Ltd. experienced significant stock price fluctuations, with a cumulative closing price increase exceeding 20% over two consecutive trading days, triggering abnormal trading conditions as per Shanghai Stock Exchange regulations [2][4]. Group 1: Stock Trading Abnormalities - The company's stock price increased by more than 20% cumulatively on February 4 and 5, 2026, indicating abnormal trading activity [2][4]. - The company confirmed that there are no undisclosed significant matters affecting the stock price, following inquiries with its controlling shareholder and actual controller [6][8]. Group 2: Company Operations and Major Events - The company reported that its production and operational activities are normal, with no significant changes in market conditions, industry policies, production costs, or sales [5]. - There are no major undisclosed events or plans, such as asset restructuring or significant business collaborations, that could impact the company [6]. Group 3: Media and Market Rumors - The company found no media reports, market rumors, or trending concepts that could significantly affect its stock price [7]. Group 4: Board and Management Assurance - The board of directors confirmed that there are no undisclosed matters that should have been reported according to the Shanghai Stock Exchange regulations, and previous disclosures do not require correction or supplementation [11].
苏州丰倍生物科技股份有限公司股票交易异常波动公告